BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23721661)

  • 1. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.
    Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH
    Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age.
    Liau JY; Liao SL; Hsiao CH; Lin MC; Chang HC; Kuo KT
    Hum Pathol; 2014 Mar; 45(3):533-9. PubMed ID: 24440092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
    van Beerendonk HM; Rozeman LB; Taminiau AH; Sciot R; Bovée JV; Cleton-Jansen AM; Hogendoorn PC
    J Pathol; 2004 Mar; 202(3):359-66. PubMed ID: 14991902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas.
    Alves MK; Lima VP; Ferrasi AC; Rodrigues MA; De Moura Campos Pardini MI; Rabenhorst SH
    APMIS; 2010 Apr; 118(4):297-307. PubMed ID: 20402675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
    Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.
    Goeppert B; Schmidt CR; Geiselhart L; Dutruel C; Capper D; Renner M; Vogel MN; Zachskorn C; Zinke J; Campos B; Schmezer P; Popanda O; Wick W; Weller M; Meyermann R; Schittenhelm J; Harter PN; Simon P; Weichert W; Schirmacher P; Plass C; Mittelbronn M
    J Neuropathol Exp Neurol; 2013 Oct; 72(10):933-41. PubMed ID: 24042196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
    Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
    Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
    Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
    Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.
    Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J
    Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.
    Lim AM; Do H; Young RJ; Wong SQ; Angel C; Collins M; Takano EA; Corry J; Wiesenfeld D; Kleid S; Sigston E; Lyons B; Fox SB; Rischin D; Dobrovic A; Solomon B
    Int J Cancer; 2014 Aug; 135(4):887-95. PubMed ID: 24436120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of multiple genes in astrocytic gliomas.
    Gonzalez-Gomez P; Bello MJ; Arjona D; Lomas J; Alonso ME; De Campos JM; Vaquero J; Isla A; Gutierrez M; Rey JA
    Int J Oncol; 2003 Mar; 22(3):601-8. PubMed ID: 12579314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
    J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the p16 gene promoter in pterygia and its association with the expression of DNA methyltransferase 3b.
    Chen PL; Cheng YW; Chiang CC; Tseng SH; Chau PS; Tsai YY
    Mol Vis; 2006 Nov; 12():1411-6. PubMed ID: 17149367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inactivation of CDKN2A gene (p16) in gallbladder carcinoma].
    Roa JC; Vo Q; Araya JC; Villaseca M; Guzmán P; Ibacache GS; de Aretxabala X; Roa I
    Rev Med Chil; 2004 Nov; 132(11):1369-76. PubMed ID: 15693199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
    Abou-Zeid AA; Azzam AZ; Kamel NA
    Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
    Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.